Views & Analysis | Perspectives on pharma industry issues

Digital

Trends & Insights, January 2026: A pharmaphorum industry rep...

Outside of the main headlines, our new Trends & Insights report looks at the wider breadth of life sciences industry news.

R&D

Net Treatment Benefit in rare disease trials: Aligning trial...

Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.

R&D

How innovative trial approaches are advancing rare disease r...

Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

R&D

Agentic AI and the human element: Building trustworthy autom...

The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.

Sales & Marketing

The drug pricing discussion that won’t disappear

Discussions of the pharma industry in the political sphere have lingered on pricing for a number of years.

Patients

Validating medications: A consumer responsibility?

Access to medications is a vital aspect of maintaining healthy lives, and the urge to invest in personal health has only grown since the COVID-19 pandemic.

Digital

An overview of AI in pharma – Part 2

According to Takeda Pharmaceuticals, the average time taken to diagnose a rare disease without technology is 7.6 years, and that comes after countless tests and physician visits.

Sales & Marketing

virtual electronic medical record interface

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Digital

Trends & Insights, January 2026: A pharmaphorum industry rep...

Outside of the main headlines, our new Trends & Insights report looks at the wider breadth of life sciences industry news.

Digital

AI scientists and the robotic labs of tomorrow

AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Oncology

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology